BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 11720431)

  • 1. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
    Bardelmeijer HA; Ouwehand M; Malingré MM; Schellens J; Beijnen JH; van Tellingen O
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
    Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
    Meerum Terwogt JM; Malingré MM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Koopman FJ; van Tellingen O; Swart M; Schellens JH
    Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
    Gelderblom H; Verweij J; Brouwer E; Pillay M; de Bruijn P; Nooter K; Stoter G; Sparreboom A
    Drug Metab Dispos; 1999 Nov; 27(11):1300-5. PubMed ID: 10534315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
    Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
    Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
    Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
    Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
    Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
    Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies.
    Nornoo AO; Zheng H; Lopes LB; Johnson-Restrepo B; Kannan K; Reed R
    Eur J Pharm Biopharm; 2009 Feb; 71(2):310-7. PubMed ID: 18793723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
    Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
    Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
    Malingré MM; Ten Bokkel Huinink WW; Duchin K; Schellens JH; Beijnen JH
    Anticancer Drugs; 2001 Aug; 12(7):591-3. PubMed ID: 11487715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
    Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
    Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.
    Shin BS; Kim HJ; Hong SH; Lee JB; Hwang SW; Lee MH; Yoo SD
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):87-94. PubMed ID: 18941747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro.
    Cornaire G; Woodley JF; Saivin S; Legendre JY; Decourt S; Cloarec A; Houin G
    Arzneimittelforschung; 2000 Jun; 50(6):576-9. PubMed ID: 10918954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; Jewell RC; Paul EM; Ten Bokkel Huinink WW; Schellens JH
    Br J Cancer; 2001 Jan; 84(1):42-7. PubMed ID: 11139311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.